Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. by Chen, V. J. et al.
British Joumal ofCancer(1998) 78(Supplement 3), 27-34
© 1998 Cancer Research Campaign
Preclinical cellular pharmacology of LY231514 (MTA):
a comparison with methotrexate, LY309887 and
raltitrexed for their effects on intracellular folate and
nucleoside triphosphate pools in CCRF-CEM cells
VJ Chen', JR Bewley', SL Andis', RM Schultz', PW lversen2, C Shih', LG Mendelsohn', DE Seitz' and JL Tonkinson'
'Division of Cancer Research and 2Division of Statistical and Mathematical Sciences, Lilly Research Laboratories, Indianapolis, IN 46285, USA
Summary LY231514 (N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]-benzoyl]-L-glutamic acid) is a new folate-
based antimetabolite currently in broad phase II clinical evaluation. Previous in vitro studies (C. Shih et al, Cancer Res 57: 1116-1123, 1997)
have suggested that LY231514 could be a multitargeted antifolate (MTA) capable of inhibiting thymidylate synthase (TS), dihydrofolate
reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT). The present study compared LY231514 with methotrexate,
raltitrexed and a glycinamide ribonucleotide formyltransferase inhibitor, LY309887, at 300, 100, 30 and 100 nM, respectively, for their effects
on intracellular folate and at 100, 66, 20 and 30 nM respectively, for their effects on nucleoside triphosphate pools in CCRF-CEM cells.
Methotrexate induced an accumulation of dihydrofolate species, together with a rapid depletion of ATP, GTP and all of the deoxynucleoside
triphosphates. LY309887 caused an accumulation of 10-formyltetrahydrofolate, a rapid loss of ATP, GTP and dATP, but a slower loss in dCTP,
dTTP and dGTP. Both LY231514 and raltitrexed had minimal effects on folate pools. In contrast, they caused rapid depletion of dTTP, dCTP
and dGTP, but induced an accumulation of dATP at different rates, with raltitrexed doing so about 2.5 times faster. Most of the observed
metabolic changes could be understood on the basis of current knowledge of folate and nucleotide metabolism. We concluded that LY231514
was distinct from methotrexate, LY309887 and raltitrexed based on their metabolic effects in CCRF-CEM cells, and that in this cell line the
inhibitory effects of LY231514 were exerted primarily against the thymidylate cycle and secondarily against de novo purine biosynthesis.
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Because of their crucial role in the biosynthesis of nucleotide
precursors, folate-requiring enzymes have been attractive targets
of cancer drug discovery for many years. In the past 20 years,
many folate analogues (Schultz, 1995) have been synthesized that
have been found to be active against TS and DHFR in the
thymidylate cycle and against GARFT, an enzyme in the de novo
biosynthesis of purines (Figure 1). A number of compounds are
currently being investigated clinically; some examples of these
include the TS inhibitors, raltitrexed (ZD 1694), AG337 and
BW1843U89, the DHFR inhibitor edatrexate and the GARFT
inhibitors lometrexol and LY309887 (Jackman and Calvert, 1995;
Hanauske, 1996; Mendelsohn et al, 1996).
LY231514 is a structurally novel folate analogue that possesses
a 6-5-fused pyrrolo[2,3-d]pyrimidine nucleus instead of the more
common 6-6-fused pteridine or quinazoline ring structures (Figure
2). In preclinical models, LY231514 has shown activity against
several tumour types. In vitro, it is highly toxic against CCRF-
CEM human leukaemia cells in cell culture, with a 50% inhibitory
concentration (for72 h continuous drug exposure and is designated
simply as IC50) of25 nm (Taylor et al, 1992; Shih et al, 1997).
Interestingly, the cytotoxicity ofLY231514 was found to be only
partly alleviated by the addition ofthymidine to the medium. While
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hypoxanthine alone afforded no reversal, the combination ofthymi-
dine and hypoxanthine completely protected cells against the toxi-
city of LY231514 (Taylor et al, 1992). The mechanisms of
protection of these nucleotide precursors are known to be intracel-
lular conversion of thymidine to thymidylate and of hypoxanthine
to the purine nucleotide inosinic acid. As such, the observed protec-
tion profile suggests that LY231514 has both antipyrimidine and
antipurine effects. Typically, the effects of TS inhibitors are fully
reversed by thymidine alone, and those of GARFT inhibitors by
hypoxanthine alone. On the other hand, DHFR inhibitors, which
are known to affect both thymidylate and purine nucleotide
biosynthesis, require the combination of thymidine and hypoxan-
thine for reversal of toxicity. However, unlike LY231514, DHFR
inhibitors are not generally significantly protected by either agent
alone.
Subsequent studies of LY231514 focused on drug uptake,
cellular retention and possible intracellular targets (Shih et al,
1997). Cellular entry of LY231514 via the reduced folate carrier
was shown by examining drug cytotoxicity against mutant lines
engineered to express different folate receptors and transport
proteins. LY231514 was shown to be and excellent substrate for
the enzyme folylpolyglutamate synthetase (Habeck et al, 1995),
suggesting the active intracellular agent to be polyglutamated
forms of LY231514. Evaluation against a panel ofpurified folate-
dependent enzymes showed the inhibitory constants (K) of
LY231514-glu5 for TS, DHFR and GARFT to be 1.3, 7.2 and
65 nM respectively. Taken together with the intracellular drug
concentration, estimated to be greater than 10 ,uM (RM Schultz,
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Figure 1 Folate metabolism. Thymidylate synthase (TS); dihydrofolate
reductase (DHFR) and serine hydroxymethyltransferase (SHMT) comprise
the thymidylate cycle; aminoimidazole carboxamide ribonucleotide
formyltransferase (AICARFT) and glycinamide ribonucleotide
formyltransferase (GARFT) are involved in de novo purine nucleotide
biosynthesis; methylenetetrahydrofolate dehydrogenase (mTHFD),
methionine synthase, and methenyltetrahydrofolate synthetase (mTHFS)
interconvert storage and catalytic forms of folate species; dehydrogenase,
cyclohydrolase and synthetase are the three activities of trifunctional Cl -
tetrahydrofolate synthase. Other folate-dependent enzymes are not shown
for the sake of clarity
unpublished observation), these data suggested that LY231514
could potentially be a multitargeted antifolate, and that combined
inhibition ofTS, DHFR and GARFT would explain the metabolite
protection profile discussed above.
The studies described below were conducted with the intention of
correlating the in vitro data obtained using purified enzymes with
changes in cellular metabolite pools. Specifically, we have exam-
ined the effects ofLY231514 on folate and nucleoside triphosphate
pools in CCRF-CEM cells. At the same time, for the purposes of
mechanistic comparison and analytical technique validation,
parallel studies were conducted with the three folate analogues
shown in Figure 2, i.e. raltitrexed, methotrexate and LY309887,
representing known inhibitors of TS, DHFR and GARFT, respec-
tively, which are three potential targets ofLY231514.
MATERIALS AND METHODS
Methylamine (40% aqueous solution) was purchased from Aldrich
Chemical Co. Sodium periodate, all of the nucleotide triphos-
phates, methotrexate [(+)Amethopterin], folic acid, p-aminoben-
zoic acid and 5-formyl-[6R,S]-THF were obtained from Sigma.
The 6(R,S)-diasteriomers of THF 5,10-methyleneTHF, 10-
formylTHF and 5-methylTHF were purchased from Dr B Schircks
Laboratories (Jona, Switzerland). [3',5',7,9'-3H(N)]-(6S)-
Leucovorin, diammonium salt ([3H]folinic acid), was obtained
from Moravek Biochemicals; raltitrexed and LY231514 were
synthesized as described previously (Shih et al, 1997). The CCRF-
CEM cells were a gift from St. Jude's Children Research Hospital,
Memphis, TN, USA. They had been maintained in culture grown
in RPMI-1640 medium, supplemented with 10% fetal bovine
serum (FBS), at 37°C under a humidified atmosphere of 5%
carbon dioxide in air. The Partisil 10 SAX column (4.6 x 250 mm)
was purchased from Whatman and the Ultrasphere IP column (4.6
x 250 mm) was purchased from Beckman Instrument. Rat plasma
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Figure 2 Structures of the antifolate compounds examined in this study
that provided the source of y-glutamyl hydrolase activity was
purchased from Pel-Freez Biologicals.
To aid detection, radiolabelling ofthe intracellular folate pool was
required, for which the medium had to be first depleted offolic acid
andthen made to afinal concentration of 100 nmwith [3H]folinic acid
(20 Ci mmol-1). In this medium, cells were seeded at 2-5 x 105 ml-l
and cultured for 16 h when cellular uptake of this vitamin, on a per
cell basis, reached a maximum (data not shown). At this time, drugs
were added and incubation was allowed to resume for the indicated
duration. The extraction and analyses offolate pools were conducted
according to the publishedmethods (Wilson andHome, 1983). At the
time of harvest, the cells were spun down, washed twice in phos-
phate-buffered saline, counted, assessed for radioactivity and imme-
diately frozen at -70°C in a pH 7.6 buffer containing 0.2 M HEPES,
2% each of ,B-mercaptoethanol and ascorbate. Subsequently, the
samples were thawed, the cells were disrupted with three short bursts
from a Bronsonprobe and brought to 900C for 2 min to inactivate the
endogenous enzymes.
After removal of cell debris and denatured proteins by centrifu-
gation for 10 min at 14 000 r.p.m. in an Eppendorf Model 5415
microcentrifuge, the supematant was combined with an aliquot of
rat plasma equal to one-third of the volume of the extract and was
incubated for 3 h to hydrolyse the polyglutamyl residues from
the endogenous folate derivatives (Wilson and Home, 1983).
Independent experiments showed that in 3 h, the level ofrat plasma
used completely converted 16 nmol ofpteroyltetra-y-L-glutamate to
folic acid. Afterwards, the proteins in the extracts were heat dena-
tured and removed by centrifugation as before. The supematant was
analysed by ion-pair chromatography as previously described
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Figure 3 Representative HPLC chromatograms from the analysis of folate pools in CCRF-CEM cells. The two halves of each panel represent simultaneous
detection of absorbance (top) and radioactivity (bottom) in column effluent. Each sample included the mixture of unlabelled standard folate derivatives co-
injected with extracts of CCRF-CEM cells containing tritium-labelled folyl metabolites prepared as described under Methods. The drug concentrations used were
1.0 pM methotrexate, 1.0 pM LY309887, 30 nM raltitrexed and 300 nM LY231514 and the drug exposure time was 4 h in all cases
(Wilson and Home, 1983). Accordingly, a Beckman IP column
(4.6 x 25 cm) was first equilibrated in 5 mm tetrabutylammonium
phosphate, pH 7.5, containing 17% ethanol. After sample injection,
the column was developed initially isocratically using the equili-
brating solvent for 40 min, then followed by linearly increasing the
ethanol proportion from 17% to 40% between 40 and 47 min, and
finally holding it at 40% for the remaining 17 min of the run. The
gradient was generated on a Spectra-Physics SP8800 ternary high-
performance liquid chromatography (HPLC) pump system, and the
effluent was monitored sequentially by absorbance at 280 nm and
by radioactivity using a Spectra Physics FOCUS optical scanning
detector and a Radiomatic Radio-chromatography Detector Series
A-100 connected in series. The delay between the two types of
measurement was less than 15 s. The radioactive peaks of cellular
folylmonoglutamates were identified by absorbance peaks of
co-injected authentic standards. The chromatography gave adequate
resolution of all of seven folate derivatives and p-aminobenzoate.
By carrying these standard compounds individually through
the entire protocol, the overall recovery of p-aminobenzoate,
10-formylTHF, THF, 5-formylTHF, 5-methylTHF and folic acid
was assessed to be 80-85%; however, the recovery for DHF was
only 43%, and all 5,10-methyleneTHF was hydrolysed to THF.
Nucleotide analyses were performed as described in the litera-
ture (Garrett and Santi, 1979). The CCRF-CEM cells were seeded
in fresh complete medium at 3 x 105 ml-' and cultured for 12-16 h
before treatment. After exposure to drugs, the cells were
harvested, washed twice in phosphate-buffered saline and
extracted three times with 3:2 ethanol-water mixture. The extracts
were combined, lyophilized and redissolved in 20 mm phosphate,
pH 7. Ribonucleoside triphosphates were analysed directly by
HPLC using a Whatman Partisil 10 SAX column (4.6 x 250 mm),
eluted isocratically with a solvent system comprising ten parts
0.4 M ammonium phosphate, pH 4.45, and one part acetonitrile.
Analysis of deoxyribonucleoside triphosphates required prior
destruction of the corresponding ribonucleoside triphosphates.
This was accomplished by making the extract to the final concen-
tration in 20 mm sodium periodate and 0.2 M methylamine. The
treated extract was analysed by HPLC using the SAX column,
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Figure 4 Effects of 0.1 pM and 1.0 pM (24 and 240 times IC50) methotrexate on intracellular folate pools in CCRF-CEM cells. The symbols used are: (0) THF;
(V) DHF + 10-formylDHF; (-) 10-formylTHF; (A) 5-methylTHF and (A) folic acid
0.1 gIM 60 -
40-
20-
1.0 IM
_ _~~~~~
- A .. A -A-A
0 1 2 3 4 0 1 2 3 4
Hours after treatment
Figure 5 Effects of 0.1 pM and 1.0 pM (34 and 340 times IC5,) LY309887 on intracellular folate pools in CCRF-CEM cells. The symbols used are: (U) 10-
formylTHF; (e) THF; (LI) 5-formylTHF; (A) 5-methylTHF. Folic acid was not detected
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Figure 6 Effects of antifolates on 10-formylTHF and THF in CCRF-CEM cells. The symbols used are: (V) raltitrexed and (-) LY231514; (n=3, mean±std error
for 4 hour time points, n=2, mean for 8 hour time points). THF represents a mixture of THF + 5, 10-methylene THF which are not distinguishable in the assay
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eluted isocratically with a solvent system comprising ten parts
0.4 M ammonium phosphate, pH 3.25, and one part acetonitrile.
These HPLC analyses were performed on a Beckman System Gold
unit, connected to a Scanning Detection Module 167 for moni-
toring the effluent spectrophotometrically at 254 nm. The output
signal was fed through a PE Nelson 900 analogue to digital
converter into aHewlett-Packard HP1000 mainframe computerfor
calculations. The nucleotide data at each time point are normalized
to the zero-time value of a particular culture. Recovery of indi-
vidual nucleotides was not assessed. However, the zero-time
values we determined forUTP, 1.28 ± 0.12; CTP, 0.53 ± 0.05; ATP,
3.64 ±0.24; GTP, 0.82 ± 0.05; dTTP, 0.046 ± 0.003; dCTP, 0.007 ±
0.001; dATP, 0.05 ± 0.002 and dGTP, 0.023 ± 0.001 nmol/million
cells (n = 12, mean ± std error) are in the same range as those
reported by others for this cell line (Kinahan et al, 1979; Pizzorno
et al, 1991).
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RESULTS
Representative HPLC profiles offolate pools extracted from CCRF-
CEM cells are shown in Figure 3. Although the HPLC method used
is capable of resolving all the naturally occurring folylmonogluta-
mate derivatives, 5,10-methyleneTHF could not be detected directly
because of its instability under the extraction condition. 5,10-
MethyleneTHF was degraded to THF, and thus the two folates were
determined together. The major folyl species ofCCRF-CEM cells in
log phase not exposed to drug consisted of 10-formylTHF, THF
(which represented THF + 5,10-methyleneTHF), a small amount of
DHF and 5-methylTHF (Figure 3). The intracellular folate content
was estimated to be 7.4 ± 0.8 glM (n = 5, mean ± standard error),
which is in good agreement with values reported for other cell lines
in the literature (Strong et al, 1990). Exposing the cells to 0.1 JIM
methotrexate (24 times theIC50 in CCRF-CEM cells) caused the loss
of 10-formylTHF, THF and 5-methylTHF with the concomitant
appearance of DHF and a new peak eluting just after DHF, which
was assumed to be 10-formylDHF (Figure 3). Increasing the concen-
tration to 1 gM methotrexate resulted in only a slightly larger effect.
Taking the recovery into consideration, the loss of 10-formylTHF,
THFand5-methylTHF accountedforabout 85% oftheaccumulation
ofDHF + 10-formylDHF (Figure 4).
The folate pools responded to LY309887 at 0.1 and 1.0 gM (34
and 340 times the IC50) similarly by an accumulation of 10-
formylTHF. This could be accounted for by the loss ofTHF (THF
+ 5,10-methyleneTHF, Figure 5), a result that is consistent with
LY309887 having created a blockage at GARFT.
Neither raltitrexed at 30 nM (20 times the IC50) nor LY231514 at
300 nm (12 times the IC50) caused a very large change in the folate
pool in 8 h (Figures 3 and 6). In particular, there was no accumula-
tion of DHF. A tenfold increase in the drug concentrations did not
result in a significantly larger effect (data not shown). The data of
LY231514 and raltitrexed in Figure 6 were compared by an
analysis of variance (ANOVA) with the experiments run on
different days treated as blocks. While there were not enough data
to make a distinction between the effects ofthe two drugs at the 8-
h time points, the 4-h time points showed that the changes induced
by raltitrexed and LY231514 were +3.5% and -1.3%, respectively
(P = 0.011), in THF (THF +5,10-methyleneTHF) and were -6.4%
and +0.3% (P = 0.003), respectively, in 10-formylTHF.
The time-dependent changes in ribonucleoside and deoxyribo-
nucleoside triphosphate pools as a result ofexposing CCRF-CEM
cells to folate-based drugs at doses about one log above IC 5 are
Drug exposure time (h)
Figure 7 Effects of antifolates on intracellular ribonucleoside triphosphate
pools. The symbols used are: (A) 66 nM (16 times IC50) methotrexate; (V) 30
nM (10 times IC50) LY309887; (both drug treatments were single
determinations); (e) 20 nM (13 times IC50) raltitrexed; (-) 300 nM (12 times
ICw) LY231514 and (o) no drug treatment; (the last three treatment were
n=3, mean±std error)
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Figure 8 Effects of antifolates on intracellular deoxyribonucleoside
triphosphate pools. The symbols used are: (A) 66 nM (16 times IC50)
methotrexate; (V) 30 nM (10 times IC5u) LY309887; both drug treatments
were single determinations); (e) 20 nM (13 times IC50) raltitrexed; (U) 300 nM
(12 times IC50) LY231514 and (o) no drug treatment; (the last three treatment
were n=3, mean±std error)
compared in Figures 7 and 8 respectively. The key points in these
data are as follows. First, only methotrexate and LY309887
affectedthe ribonucleotide pools greatly. The effect was antipurine
in nature, with a rapid depletion in both ATP and GTP, and minor
modulation in UTP and CTP. Second, neither raltitrexed nor
LY231514 had a significant effect on any of the ribonucleoside
triphosphate pools at concentrations 12 times the IC50 (Figure 7) or
120 times IC50 (data not shown). Third, all the folate-based drugs
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we tested greatly affected the deoxyribonucleotide pools (Figure
8). In response to LY309887, dATP declined rapidly, followed
closely by dCTP and then later by dGTP and dTTP at a slower
rate. Methotrexate rapidly depleted all four deoxyribonucleotide
pools. Both LY231514 and raltitrexed caused similar losses in
dTTP, dCTP and dGTP but induced a difference in the rate of
dATP accumulation. Quantitatively, the actual increase in dATP
(relative to time zero) due to raltitrexed was found to be higher
than that due to LY231514 at 12 h (81% vs 33%, P = 0.0037) and
at 24 h (215% vs 81%, P < 0.0001). This was determined by
analysing the logarithm of the relative dATP measurements with a
repeated measures, fixed effects ANOVA and comparing the two
drugs at each time point using the Hochberg multiple comparison
procedure to control the type I error rate (Benjamini and
Hochberg, 1995).
DISCUSSION
Several previous studies using cell culture as well as purified
folate-dependent enzymes have suggested that the mechanism of
action ofLY231514 could potentially be due to interference ofthe
activities of multiple folate-dependent enzymes, including TS,
DHRF and GARFT (Shih et al, 1997). In order to gain further
insight into how inhibition at these targets might contribute to
cytotoxicity, the present study was initiated to examine the effects
of LY231514 on cellular metabolism, as indicated by intracellular
folate and nucleotide pools. Parallel studies were carried out with
methotrexate, LY309887 and raltitrexed for the combined purpose
of both ascertaining the behaviour of representative inhibitors of
each of the potential targets of LY231514 as well as validation of
the analytical techniques.
Our data for the effects of methotrexate and LY309887 on
cellular folate pools were fully consistent with the known mecha-
nism of action of these drugs. Accumulation of DHF and 10-
formylDHF in cells exposed to methotrexate is a well documented
consequence of DHFR inhibition (Allegra et al, 1986; Ackland
and Schilsky, 1987; Baram et al, 1987; Morrison and Allegra,
1989; Matherly and Muench, 1990; Trent et al, 1991). In our
analysis, we were able toquantitatively account for the build-up in
DHF species from the combined depletion in 10-formylTHF, THF
and 5-methylTHF. However, we observed a complete disappear-
ance of 10-formylTHF, while others have previously reported only
a partial loss. This difference might have resulted from a combina-
tion ofthe use ofdifferent folates as the source ofthe radiolabel, as
well as the total folate concentration in the cell culture medium.
With 100 nM 5-formylTHF as the source of label and folate, it
would not be unreasonable to expect only a small amount of 5-
methylTHF. The trace amount of folic acid present was probably
due to spurious oxidation during extraction, as there is no known
cellular mechanism for conversion of 5-formylTHF to folic acid.
Thus, during inhibition of DHFR, a depletion in the functional
folatepool involved the loss of 10-formylTHF. Other investigators
have reported labelling with 2.3 gM folic acid, which would result
in higher 5-methylTHF and folic acid levels (Allegra et al, 1986;
Baram et al, 1987; Matherly and Muench, 1990; Trent et al, 1991).
These were expected to be the first folyl species to be lost, when
DHFR was inhibited. However, in their instance, depletion of
folate stopped as a result of inhibition of TS by the accumulation
of 10-formylDHF, before significant loss of 10-formylTHF.
The accumulation of 10-formylTHF observed with LY309887
(Figure 5) is consistent with inhibition at GARFT (Habeck et al,
1994). On the other hand, the anticipated consequence of TS inhi-
bition is an accumulation of 5,10-methyleneTHF, which, unfortu-
nately, is a folate species that could not be differentiated from THF
in our assay. Therefore, if raltitrexed had caused such an increase
in 5,10-methyleneTHF at the expense of THF, it would not have
been detected. Thus, the lack of a substantial effect of raltitrexed
on the folate pool was not an unexpected result. Nevertheless,
exposure to raltitrexed did trigger a very slight rise in the level of
THF and a compensatory fall in that of 10-formylTHF (Figure 6).
An equally small effect on the folate pool was observed with
LY231514, with a trend for THF and 10-formylTHF consistently
opposite to that for raltitrexed. Based on an analogy to the
observed accumulation of 10-formylTHF by LY309887 (Figure
5), the differential effects on 10-formylTHF and THF induced by
LY231514 and raltitrexed (Figure 6) might be attributable to a
difference in their effects on GARFT. This hypothesis, however,
would have to be confirmed by direct measurement of metabolic
flux through the de novo purine nucleotide biosynthetic pathway.
The major message from the folate analysis was the lack of
DHF accumulation induced by either raltitrexed or LY231514 in
CCRF-CEM cells under very similar conditions in which DHF
was detected with methotrexate. When TS was strongly inhibited,
there would be little or no conversion of 5,10-methyleneTHF to
DHF, and DHFR would be effectively inactive. Thus, the lack of
intracellular accumulation of DHF by LY231514 does not contra-
dict the fact that this drug inhibits purified DHFR in vitro.
However, it does suggest the primary target ofLY231514 to be TS
in CCRF-CEM cells. In the presence of significant TS inhibition,
it is difficult to study the metabolic effect of a drug on DHFR.
Concurrent inhibition of two sequential steps in the same meta-
bolic pathway can be redundant with respect to the end product.
The intracellular level of each nucleotide is a balance of
synthesis, use and salvage (Kornberg, 1980; Reichard, 1988). The
biosynthetic pathways ofindividual nucleotides are interconnected
in that they share several common intermediates, and that the end
product of one pathway serves as an allosteric regulator of the
enzymes in the others. Moreover, the ribonucleotides are the
precursors for RNA, as well as for their respective deoxyribose
counterparts, and the syntheses ofdeoxyribonucleotides and DNA
are under cell cycle regulation.
Against this background is the well known fact that
methotrexate exhibits inhibitory activities against the biosynthesis
ofboth pyrimidine and purine nucleotides (Ackland and Schilsky,
1987). Thus, the depletion of both ATP and GTP caused by
methotrexate observed here and by others (Kinahan et al, 1979;
Taylor et al, 1982a and b) is consistent with the antipurine effect
of methotrexate. Furthermore, similar depletion of ATP and GTP
was observed with the GARFT inhibitor LY309887 and was
reported for lometrexol (Pizzorno et al, 1991; Chong and
Tattersall, 1995), as well as for other antipurine compounds, such
as 6-methylmercaptopurine ribonucleoside (Cohen and Sadee,
1983). Our data for methotrexate and LY309887 implied that, if
there was an antipurine effect, it should have been evident in the
ribonucleotide pools. Thus, it was not surprising that raltitrexed,
having no known antipurine effect, did not show any significant
effects on ribonucleoside triphosphate levels. Similar results
were obtained with LY231514, despite previous reports on its inhi-
bition on purified GARFT (Kj= 65 nm for LY231514-glu5)
(Shih et al, 1997) in vitro. In the presence ofpossible salvage and
other compensatory pathways, the magnitude of the anti-GARFT
effect of LY231514 might be insufficient to cause significant
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impact on the intracellular ribonucleoside triphosphate pools in
CCRF-CEM cells.
Depletion ofintracellular dTTP is the most notable consequence
of a retardation of the thymidylate cycle, involving inhibition of
either TS or DHFR (Kinahan et al, 1979; Jackson, 1992; Aherne et
al, 1996; Kunz, 1996; Weber et al, 1996). The fall of dTTP
observed with methotrexate, raltitrexed and LY231514 was very
rapid. On the other hand, although LY309887 also depleted dTTP,
it did so much more gradually.
It is well known that when cells are nutritionally deprived of
thymine, the intracellular level of dTTP falls together with simul-
taneous perturbations in the other three deoxyribonucleoside
triphosphates (Kunz, 1996). For example, studies with 5-fluo-
rodeoxycytidine and CB3717 have shown a rise in dATP level and
a fall in dGTP level accompanying dTTP depletion (Newman and
Santi, 1982; Jackson et al, 1983; Kwok and Tattersall, 1992). With
raltitrexed and LY231514, we observed an accumulation of dATP
together with the disappearance of both dCTP and dGTP,
concomitant with dTTP depletion. The changes in dCTP and
dGTP may be rationalised by what is known about dCMP deami-
nase and ribonucleoside diphosphate reductase, the two enzymes
that control the biosynthesis of deoxyribonucleotide (Kinahan et
al, 1979; Kornberg, 1980; Oliva et al, 1996). It is known that
dCMP deaminase is inhibitable by dTTP. Possibly, the fall of
dTTP as a result of TS inhibition could restore dCMP deaminase
activity, causing dCMP to be converted to dUMP. This could in
turn lead to dCTP depletion via the rapid intracellular equilibrium
between the mono-, di- and triphosphate forms of the nucleoside.
At the same time, ribonucleoside diphosphate reductase, which
converts GDP to dGDP, is allosterically enhanced by dTTP and
inhibited by dATP (Reichard, 1988). Thus, the fall of dGTP
observed with reltitrexed and LY231514 here may be consistent
with the retardation in the synthesis of dGDP under conditions of
low dTTP and high dATP.
The mechanism for the changes in dATP levels is not well
understood. However, it is interesting to note that for
methotrexate, a drug with both antipyrimidine and antipurine
effects, depletion of dTTP occurred without a concommitant
increase in dATP. Furthermore, Chong and Tattersoll (1995)
reported that the combination of a GARFT inhibitor and a TS
inhibitor prevented the rise in the dATP pool seen with the TS
inhibitor alone. Based on these observations, the difference in the
rate of dATP accumulation induced by raltitrexed and LY231514
would be attributable to the difference in antipurine effect of the
two drugs, a hypothesis that can be verified by direct evaluation of
the metabolic flux from glycine to inosinic acid.
In conclusion, our study showed that the new folate analogue
LY231514 was an antimetabolite distinct from methotrexate,
LY309887 and raltitrexed. The data presented above are consistent
with LY231514 in affecting the thymidylate cycle as well as
possibly de novo purine nucleotide biosynthesis in CCRF-CEM
cells. Although, in the present study with CCRF-CEM cells, a
significant perturbation of the ribonucleotide pools was not
observed with LY231514, comparing the changes in dATP induced
with other folate-based drugs provided evidence suggestive of the
possible presence ofan effect on purine nucleotides. The inhibition
of the thymidylate cycle contributed by strong inhibition of TS
could mask the effect of LY231514 on DHFR, as a result of the
two enzymes being sequential steps in the same metabolic
pathway. As such, it will be interesting to study a cell line with
overexpressed TS levels in future. Evaluation in other cell lines is
in progress to confirm the generality of the observations reported
in this paper. The phase I evaluation of LY231514 has been
completed (Rinaldi et al, 1995, 1996; McDonald et al, 1996). A
broad phase II clinical study using the q21 days at 500-600 mg m-2
is currently in progress and preliminary results indicate early
favourable responses in several tumour types (Clarke et al, 1997;
Cripps et al, 1997; John et al, 1997; Miller et al, 1997; Rusthoven
et al, 1997; Smith et al, 1997). It will be very interesting to see how
the mechanistic subtleties between the folate-based drugs
discussed in this paper eventually translate into differences in
clinical efficacy and toxicity.
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